Physician profile
Luis E Raez
NPI 1922030071
$115,892.39
in general payments reported to CMS, 2019-2025
46 companies · $33K in 2025
The $33K reported for 2025 was more than what 95% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $888 · 2020: $752 · 2021: $1,800 · 2022: $2,132 · 2023: $33K · 2024: $44K · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $82K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $8,355 · Honoraria: $3,880 · Charitable Contribution: $1,500 · Travel and Lodging: $757 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $82,037.98 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,692.00 |
| Food and Beverage | $8,355.18 |
| Honoraria | $3,880.00 |
| Charitable Contribution | $1,500.00 |
| Travel and Lodging | $756.95 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $15,197.85 | 2019-2025 | Imfinzi, Tagrisso, Imjudo |
| Bayer Healthcare Pharmaceuticals INC. | $13,647.91 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $10,249.22 | 2019-2024 | Opdivo |
| Janssen Scientific Affairs, LLC | $7,955.52 | 2024-2025 | Rybrevant |
| Novartis Pharmaceuticals Corporation | $7,437.48 | 2022-2025 | |
| Abbvie INC. | $7,050.00 | 2024-2025 | |
| Emd Serono, INC. | $6,333.94 | 2022-2025 | |
| Janssen Biotech, INC. | $5,805.81 | 2019-2025 | Rybrevant, Erleada, Darzalex |
| Pfizer INC. | $5,627.48 | 2023-2025 | |
| Eli Lilly and Company | $5,505.32 | 2023-2025 | |
| Daiichi Sankyo INC. | $5,085.67 | 2022-2025 | Enhertu, Datroway |
| Merck Sharp & Dohme LLC | $4,322.72 | 2023-2024 | Lynparza, Keytruda |
| Takeda Pharmaceuticals U.S.A., INC. | $3,069.99 | 2021-2024 | Alunbrig |
| Lilly USA, LLC | $2,721.31 | 2019-2023 | |
| Immunitybio, INC. | $2,500.00 | 2025 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,437.63 | 2019-2025 | |
| Nuvation Bio INC. | $2,100.00 | 2025 | Ibtrozi |
| Amgen INC. | $1,907.45 | 2021-2025 | Imdelltra (Amg757) |
| Novocure INC. | $1,486.71 | 2024 | Optune Lua (Novottf-200t) |
| Coherus Oncology, INC. | $838.86 | 2022-2025 | Loqtorzi |
| Gilead Sciences, INC. | $688.00 | 2023-2025 | Trodelvy |
| Sirtex Medical INC | $589.80 | 2022-2023 | Sir-Spheres Microspheres |
| Tempus Ai, INC | $533.29 | 2024-2025 | Xt Cdx, Tempus Pixel |
| Genentech USA, INC. | $456.19 | 2020-2023 | Tecentriq |
| Jazz Pharmaceuticals INC. | $455.57 | 2021-2024 | |
| Exelixis INC. | $347.22 | 2025 | Cabometyx |
| Foundation Medicine, INC. | $317.50 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $178.43 | 2021-2025 | Libtayo |
| Eisai INC. | $168.12 | 2019-2021 | |
| Adaptive Biotechnologies Corporation | $149.12 | 2023 | Clonoseq |
| Labcorp Holdings INC. | $122.34 | 2022 | |
| Genzyme Corporation | $102.94 | 2024 | |
| Stemline Therapeutics INC. | $101.35 | 2023 | Orserdu |
| Genmab U.S., INC. | $100.64 | 2023 | |
| Caris Mpi, INC. | $97.17 | 2025 | Mi Cancer Seek |
| Array Biopharma INC | $52.91 | 2024 | Lorbrena |
| Genetix Biotherapeutics INC | $32.17 | 2024 | |
| Aadi Bioscience, INC. | $27.09 | 2025 | Fyarro |
| Seagen INC. | $23.79 | 2019 | |
| Karyopharm Therapeutics INC. | $22.82 | 2022 | |
| G1 Therapeutics, INC. | $20.15 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $12.81 | 2020 | |
| Astellas Pharma US INC | $12.10 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Raez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.